Parametric Portfolio Associates’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Parametric Portfolio Associates’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-564	Closed	-$26K	–	3786
2021 Q4	$26K	Buy	+564	New	+$37.9K	﹤0.01%	3617
2019 Q1	–	Sell	-174	Closed	-$19K	–	3986
2018 Q4	$19K	Buy	+174	New	+$34.8K	﹤0.01%	3886
2014 Q2	–	Sell	-20	Closed	-$43K	–	3805
2014 Q1	$43K	Buy	20 +1	+5%	+$2.49K	﹤0.01%	3788
2013 Q4	$43K	Buy	+19	New	+$43.5K	﹤0.01%	3788

Other funds holding ONCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Parametric Portfolio Associates's ONCT Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2022, closing a stake of 564 shares — an estimated $26K sold.

Parametric Portfolio Associates first reported a position in ONCT in Q4 2013 and held it in 4 quarters. The position peaked at $43K in Q1 2014. 78 funds tracked by Wall St. Rank hold ONCT as of Q1 2022.

Parametric Portfolio Associates reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Parametric Portfolio Associates sold 564 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $26K.
Parametric Portfolio Associates first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2013 and held it in 4 quarters.
Parametric Portfolio Associates's Oncternal Therapeutics, Inc. Common Stock position peaked at $43K in Q1 2014.
78 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.